Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ConvaTec ( (GB:CTEC) ) has issued an update.
ConvaTec Group PLC has announced the purchase of 1,137,931 ordinary shares as part of its $300 million share buyback program, initiated on August 20, 2025. The shares, acquired through UBS AG London Branch, will be held in treasury, impacting the company’s total voting rights and potentially influencing shareholder interests under the Financial Conduct Authority’s regulations.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.
ConvaTec’s strong financial performance and strategic positioning are tempered by bearish technical indicators and a high valuation. Regulatory challenges may pose risks, but the company’s innovation pipeline and operational strength support a moderately positive outlook.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing solutions for advanced wound care, ostomy care, continence and critical care, and infusion devices. The company aims to enhance the lives of patients and healthcare providers through its innovative products and services.
Average Trading Volume: 8,093,515
Technical Sentiment Signal: Hold
Current Market Cap: £4.76B
See more data about CTEC stock on TipRanks’ Stock Analysis page.